Vivici awarded €12.5m in EIC Accelerator funding
The June 2026 blended-finance award backs expansion of the Dutch protein-ingredients business.
Announced on 17 June, the award supports wider supply and market access for Vivici’s Vivitein proteins and further ingredient development. The EIC Accelerator combines grants with equity investment; this announcement describes an award rather than confirming that the whole amount has been disbursed.
Vivici had commercialised beta-lactoglobulin and introduced a second ingredient, lactoferrin, in the US. The new support is intended to help the business meet demand from food and nutrition companies.
Use of funds
Scale market access and supply of Vivitein ingredients
Develop further functional-protein innovation